Drugs / CTX-009
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07392957 | Jun 2026 → Jun 2029 expected | glioblastoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06548412 | Jan 2025 → May 2027 expected | biliary tract cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04492033 | Jun 2020 → Jan 2024 | biliary tract cancer, cancer of unknown primary site | Handok Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07662031 | Aug 2026 → Aug 2030 expected | colorectal cancer | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05513742 | Dec 2022 → May 2025 | colon carcinoma, rectal carcinoma | Compass Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05506943 | Jan 2023 → Dec 2026 expected | ampulla of vater cancer, cholangiocarcinoma, gallbladder cancer | Compass Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04492033 ↗ |
| Known as | ABL001 | “CTX-009 (ABL001) will be administered biweekly.” NCT04492033 ↗ |
| Known as | Tovecimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662031 ↗ |
| Action | Inhibit | “CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab” NCT07392957 ↗ |
| Route | Intravenous | “IV infusion on day 1 and 14 of every 28 day cycle” NCT05506943 ↗ |
| Target | DLL4 | “CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A” PMID 38861293 ↗ Jun 2024 |